Resolution criteria:
Approval from a recognized regulatory body, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent organizations in other countries.
Categories:
Targeting Viral Infections: This category encompasses the use of CRISPR technology to edit human cells in a way that makes them resistant to infections by specific viruses, such as HIV.
Cancer treatment: Approval for therapies that use CRISPR to modify human cells to fight various forms of cancer, such as editing immune cells to target cancer cells more effectively.
Anti-aging therapies: Approval for treatments aimed at delaying the aging process or reversing age-related deterioration at the genetic level.
Enhancing human physical abilities: Approval for applications designed to enhance or improve human physical capabilities beyond the therapeutic treatment of disease, including but not limited to increased strength, endurance, or other physical traits.
Date: The first regulatory approval must be documented on or before December 31, 2030